Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3442 clinical trials
Adaptative MR-Guided Stereotactic Body Radiotherapy of Liver Tumors

The incidence of primary liver cancer increases due to the increase in chronic liver diseases induced by excessive alcohol consumption, hepatitis B and C viruses, and excess fat in the liver. Surgical excision of these liver lesions is the reference treatment but it cannot always be realised.

colorectal cancer
metastasis
skin cancer
stereotactic radiation therapy
chelates
  • 0 views
  • 16 Feb, 2024
  • 1 location
Monovalent Recombinant COVID19 Vaccine

This is a study to test a new vaccine (Covax-19) against COVID-19. COVID-19 is a potentially deadly disease that is caused by a new strain of coronavirus called SARS-CoV-2. To date, SARS-CoV-2 has infected over 4 million people worldwide resulted in the deaths of over three hundred thousand people.

coronavirus infection
acute respiratory syndrome (sars)
SARS
covid-19
vaccination
  • 0 views
  • 16 Feb, 2024
  • 1 location
The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

This is a prospective, single-center, open-label, single-dose, Phase 1 study, to assess the effect of moderate hepatic impairment due to liver cirrhosis on the pharmacokinetics of aprocitentan (ACT-132577).

moderate hepatic insufficiency
follicle stimulating hormone
kidney function tests
aprocitentan
cirrhosis
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies

This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study of oral tazemetostat in subjects with either advanced solid tumors, or hematological malignancies and normal hepatic function or moderate, or severe hepatic impairment.

opportunistic infection
targeted therapy
malabsorption syndrome
HIV Infection
hematologic malignancy
  • 0 views
  • 16 Feb, 2024
  • 5 locations
Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.

microwave ablation
sintilimab
hepatocellular carcinoma
unresectable hepatocellular carcinoma
TACE
  • 0 views
  • 16 Feb, 2024
  • 1 location
Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.

hepatocellular carcinoma
cirrhosis
carcinoma
  • 0 views
  • 16 Feb, 2024
  • 1 location
A Study of Laparoscopic Middle Hepatic Vein Guidance and Traditional Anatomic Hemihepatectomy

The study, entitled "RCT study of laparoscopic middle hepatic venous guidance versus conventional ananatomical hemihepatectomy", was designed to compare the efficacy of two different ananatomical hemihepatectomy procedures under laparoscopy.

hypertension
hepatocellular carcinoma
cirrhosis
carcinoma
vascular invasion
  • 0 views
  • 16 Feb, 2024
  • 1 location
Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

To investigate the potential efficacy of dupilumab in the treatment of moderate to severe chronic hepatic pruritus.

chronic pruritus
dupilumab
  • 0 views
  • 16 Feb, 2024
  • 1 location
Longitudinal Immune-phenotyping of HCC Following MK-3475

The study comprises a main study of pembro-treated HCC patients and a sub-study of untreated HCC patients. In the main study, patients will be treated with pembrolizumab as neoadjuvant treatment approximately 4 weeks prior scheduled surgery. Adjuvant treatment with pembrolizumab with commence at approximately 4 weeks post-surgery for up to …

hepatectomy
pembrolizumab
carcinoma
blood transfusion
radiofrequency ablation
  • 0 views
  • 16 Feb, 2024
  • 1 location
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC

Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative conversion therapy in patients with potentially resectable HCC. Investigator hypothesized that lenvatinib may be an effective …

  • 0 views
  • 16 Feb, 2024
  • 4 locations